ReviewDrug design, development and therapy2014
Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss.
Review in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Identification of SDC4 as a potential target for obesity via integrated analysis of the lncRNA-miRNA-mRNA network in visceral adipose tissue.Adipocyte · 2025Article
- Dietary uridine improves lipid homeostasis in high-fat diet-induced obese mice by regulating liver gene expression and metabolomic profiles.Frontiers in nutrition · 2025Article
- Relationship between Physical Activity, Mediterranean Diet and Emotional Intelligence in Spanish Primary Education Students.Children (Basel, Switzerland) · 2023Article
- Elucidating Drug-Like Compounds and Potential Mechanisms of Corn Silk (Current issues in molecular biology · 2021Article
- A Review on the Role of Food-Derived Bioactive Molecules and the Microbiota-Gut-Brain Axis in Satiety Regulation.Nutrients · 2021Review
- Negative Modulation of the Metabotropic Glutamate Receptor Type 5 as a Potential Therapeutic Strategy in Obesity and Binge-Like Eating Behavior.Frontiers in neuroscience · 2021Article
- Article
- α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3.International journal of obesity (2005) · 2019Article
- Effect of Vitamin D Supplementation on Weight Loss, Glycemic Indices, and Lipid Profile in Obese and Overweight Women: A Clinical Trial Study.International journal of preventive medicine · 2018Article
- Medication and nutritional supplement use before and after bariatric surgery.Sao Paulo medical journal = Revista paulista de medicina · 2016Article
- FNDC5 is produced in the stomach and associated to body composition.Scientific reports · 2016Article
- Review
- Peripheral signals mediate the beneficial effects of gastric surgery in obesity.Gastroenterology research and practice · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of obesity has increased worldwide, and approximately 25%-35% of the adult population is obese in some countries. The excess of body fat is associated with adverse health consequences. Considering the limited efficacy of diet and exercise in the current obese population and the use of bariatric surgery only for morbid obesity, it appears that drug therapy is the only available method to address the problem on a large scale. Currently, pharmacological obesity treatment options are limited. However, new antiobesity drugs acting through central nervous system pathways or the peripheral adiposity signals and gastrointestinal tract are under clinical development. One of the most promising approaches is the use of peptides that influence the peripheral satiety signals and brain-gut axis such as GLP-1 analogs. However, considering that any antiobesity drug may affect one or several of the systems that control food intake and energy expenditure, it is unlikely that a single pharmacological agent will be effective as a striking obesity treatment. Thus, future strategies to treat obesity will need to be directed at sustainable weight loss to ensure maximal safety. This strategy will probably require the coadministration of medications that act through different mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.